AERIAL Trial: Antiplatelet Therapy in Heart Transplantation

Launched by OTTAWA HEART INSTITUTE RESEARCH CORPORATION · Feb 22, 2021

Keywords

ClinConnect Summary

The AERIAL Trial is a research study looking at how early treatment with certain medications, called antiplatelet therapies, can help prevent a serious condition known as cardiac allograft vasculopathy (CAV) in patients who have received a heart transplant. CAV is a common complication that causes the arteries of the transplanted heart to become narrow, which can lead to problems with how well the heart functions. The goal of this trial is to see if starting these medications soon after the transplant can help avoid this issue and to determine if a larger study should be conducted in multiple locations.

To participate in this trial, individuals must be at least 18 years old and have received a heart transplant. However, some people might not be eligible, especially those with certain allergies or medical conditions, such as recent bleeding issues or specific blood disorders. If you join the trial, you will be closely monitored to see how well the treatments work and if they are safe. This study is currently recruiting participants, and it is an important step in improving the care of heart transplant patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Heart transplant
• • 2. Age ≥18 years
• • 3. Able to provide informed consent
• Exclusion Criteria:
• • 1. Allergy or known intolerance to aspirin
• • 2. Allergy or known intolerance to clopidogrel
• • 3. Intracranial hemorrhage ≤14 days
• • 4. Bleeding disorder
• • 5. Platelet count \<50 x 109/L
• • 6. History of aspirin related gastrointestinal bleeding or ulcers
• • 7. Non-cardiac indication for antiplatelet therapy
• • 8. Anticoagulation \>3 months
• • 9. Allergy to iodinated contrast
• • 10. Unable to undergo coronary angiography due to glomerular filtration rate ≤30 mL/min/1.73 m2 for non-dialysis patients
• • 11. Unable to undergo coronary angiography due to unsuitable vascular access
• • 12. Combined solid organ transplantation.